<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02356913</url>
  </required_header>
  <id_info>
    <org_study_id>F-IN112</org_study_id>
    <secondary_id>NIC/2013/1012</secondary_id>
    <nct_id>NCT02356913</nct_id>
  </id_info>
  <brief_title>Comparison of Pharmacokinetic Profiles of 3 New Nicotine Gum Formulations With a Reference Gum</brief_title>
  <official_title>A Pilot, Open Label, Randomised, Single Dose, Four-Period, Four-Treatment, Four-Sequence, Four Way Crossover Comparative Pharmacokinetic Study of Three Different 4 mg Nicotine Chewing Gum Test Formulations of Fertin Pharma A/S, Denmark With Nicorette Freshmint 4 mg Medicated Chewing Gum of McNeil Denmark ApS as Reference Formulation in Healthy, Adult, Human Smokers Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fertin Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fertin Pharma A/S</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the pharmacokinetic (PK) profiles and assess&#xD;
      bioequivalence between three new nicotine gum formulations and a reference nicotine gum in&#xD;
      healthy smokers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum observed nicotine concentration in plasma (Cmax)</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration vs. time curve until the last measurable concentration (AUC0-t)</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration vs. time curve until infinity (AUC∞)</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>12 hours from start of product administration</time_frame>
    <description>The time of occurrence of Cmax following product administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel</measure>
    <time_frame>12 hours</time_frame>
    <description>The apparent Terminal Elimination Rate Constant of nicotine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T½</measure>
    <time_frame>12 hours</time_frame>
    <description>The apparent Terminal Elimination Half-life of nicotine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of nicotine released from the gum during 30 minutes of chewing</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Gum A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg nicotine gum; single dose; chewed 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gum B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg nicotine gum; single dose; chewed 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gum C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg nicotine gum; single dose; chewed 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicorette Freshmint</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg nicotine gum; single dose; chewed 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine gum</intervention_name>
    <arm_group_label>Gum A</arm_group_label>
    <arm_group_label>Gum B</arm_group_label>
    <arm_group_label>Gum C</arm_group_label>
    <arm_group_label>Nicorette Freshmint</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, adult, human smoker volunteers of any race within the age between 18 to 55&#xD;
             years.&#xD;
&#xD;
          -  Willingness to provide informed consent to participate in the study&#xD;
&#xD;
          -  Body Mass Index (BMI)&gt; 18.5 kg/m2 to &lt; 28.0 kg/m2.&#xD;
&#xD;
          -  Smoke 5-10 cigarettes per day continuously for the last three (3) months&#xD;
&#xD;
          -  Exhaled carbon monoxide ≥ 10 ppm at screening visit&#xD;
&#xD;
          -  Successfully complete the training session&#xD;
&#xD;
          -  Medically healthy subjects with clinically normal laboratory profiles, vital signs and&#xD;
             ECGs as deemed by the Clinical Investigator&#xD;
&#xD;
          -  Subject who are not in the process of quitting smoking&#xD;
&#xD;
          -  Hemoglobin: ≥12.0 gm% for male and ≥11.5 gm% for female&#xD;
&#xD;
          -  Absence of disease markers of HIV I &amp; II, HBsAg, HCVAb and P24 antigen test.&#xD;
&#xD;
          -  Females of childbearing age must be practicing an acceptable form of birth control for&#xD;
             at least six months before screening and continue practicing an acceptable form of&#xD;
             birth control during the study, unless they have had bilateral oophorectomy or tubal&#xD;
             ligation or male partner has had vasectomy.&#xD;
&#xD;
          -  Females of childbearing age agree to use acceptable form of birth control until the&#xD;
             drug is washed out from the body i.e. 3 days after last dosing, unless male partner&#xD;
             has had vasectomy.&#xD;
&#xD;
          -  Absence of significant disease or clinically significant abnormal laboratory values on&#xD;
             the laboratory evaluations, medical history or physical examination during the&#xD;
             screening.&#xD;
&#xD;
          -  Have a normal 12-lead ECG or one with abnormality considered clinically insignificant.&#xD;
&#xD;
          -  Have a normal chest X-ray (P. A. view).&#xD;
&#xD;
          -  Comprehension of the nature and purpose of the study and willingness to comply with&#xD;
             the requirements of the entire procedure.&#xD;
&#xD;
          -  Negative Breath alcohol test at every check in.&#xD;
&#xD;
          -  Negative serum β-HCG at the time of screening and at every check in (for females&#xD;
             only).&#xD;
&#xD;
          -  Negative urine drug of abuse test (Barbiturates, Benzodiazepines, Opioids, Cocaine,&#xD;
             Cannabinoids and Amphetamine, etc.) at every check-in. (This test will be done at the&#xD;
             clinical facility).&#xD;
&#xD;
          -  Willing to use Nicotine chewing gum during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of; drug abuse within the past year; hypersensitivity or&#xD;
             idiosyncratic reaction to Nicotine or the resin of the gum preparation; any form of&#xD;
             oral and/or pharyngeal inflammation; any form of oral lesions and/or gum disease or&#xD;
             temperomandibular joint dysfunction; dentures or any dental work that could, in the&#xD;
             opinion of the Investigator, affect the conduct of the study (including missing&#xD;
             molars);&#xD;
&#xD;
          -  Any major illness in the last three months or any significant ongoing chronic medical&#xD;
             illness.&#xD;
&#xD;
          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or&#xD;
             psychiatric disease.&#xD;
&#xD;
          -  Active deep vein thrombosis, arterial thromboembolic disorders or a history of these&#xD;
             conditions&#xD;
&#xD;
          -  History of or current gastro-intestinal diseases influencing drug absorption.&#xD;
&#xD;
          -  Subjects who had been on a special diet (for whatever reason) during the 28 days prior&#xD;
             to the first dose and throughout the study.&#xD;
&#xD;
          -  Those who have used tobacco or nicotine containing products within 24 hours prior to&#xD;
             the study drug administration on each study day.&#xD;
&#xD;
          -  Subjects with carbon monoxide levels greater than or equal to 8 ppm in the morning&#xD;
             prior to dosing.&#xD;
&#xD;
          -  Suffer from xerostomia (dry mouth).&#xD;
&#xD;
          -  Subjects using any smoking cessation aids such as nicotine replacement therapy (NRT),&#xD;
             buproprion or varenicline during the last 3 months.&#xD;
&#xD;
          -  History of neuropsychiatric diseases.&#xD;
&#xD;
          -  History of breast cancer, endometrial cancer or other estrogen-dependent neoplasia,&#xD;
             endometriosis and undiagnosed vaginal bleeding (for females only).&#xD;
&#xD;
          -  Consumption of xanthine containing food and beverages [chocolates, tea, coffee or cola&#xD;
             drinks] less than 48.0 hours prior to check in.&#xD;
&#xD;
          -  Consumption of grapefruit/ Seville orange, grapefruit/ Seville orange juice products&#xD;
             and poppy- containing food and beverages less than 48.0 hours prior to every check in.&#xD;
&#xD;
          -  History of alcoholism (more than two years), moderate drinkers (more than three drinks&#xD;
             per day) or having consumed alcohol less than 48.0 hours prior to check in.&#xD;
&#xD;
          -  Participation in any clinical trial within last three months.&#xD;
&#xD;
          -  History of difficulty with donating blood or difficulty in accessibility of veins in&#xD;
             left or right arm.&#xD;
&#xD;
          -  Donation of blood (one unit or 350 mL or more) within last three months prior to&#xD;
             receiving the first dose of investigational products.&#xD;
&#xD;
          -  Use of any prescription drug therapy or over the counter (OTC) drugs or herbal&#xD;
             products within two weeks prior to receiving the first dose of study medication and&#xD;
             during the study [includes catecolamines, theophylline, clozapine and ropinirol].&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Breast feeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tejas Acharya, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Synchron Research Services Pvt. Ltd.</affiliation>
  </overall_official>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2015</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

